SC1-PM-09-2016 New therapies for chronic diseases - development of a novel Ca2+ channel blocker as novel cardiovascular drug
A UK university has discovered a class of natural compounds able to target transient receptor potential channels (TRPC) which are therapeutic targets for several disorders. The project aims to further examine the efficacy of these natural compounds using disease models, pharmacokinetics, and healthy volunteers. Academic partners (particularly with in vivo disease models) and pharmaceutical companies are sought to join the consortium for this Horizon 2020 project proposal.